Fosun Pharma unit Henlius secures global license for two T-cell engager products from Amberstone
On September 23, 2026, Shanghai Fosun Pharmaceutical announced its subsidiary Henlius signed a collaboration and license agreement with Amberstone Biosciences. Henlius receives an exclusive worldwide license to research, develop, manufacture, and commercialize two T-cell engager products targeting tumor antigens, using Amberstone's T-MATE platform. Henlius will pay up to $236.16 million in upfront and milestone payments, plus up to $652 million in sales milestones.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Fosun Pharma unit Henlius signs global license deal with Amberstone for T-cell engager products
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced on the evening of September 23, 2026, that its controlling subsidiary Shanghai Henlius Biotech, Inc. has entered into a Collaboration and License Agreement with Amberstone Biosciences, Inc. Under the agreement, Henlius receives an exclusive global license to research, develop, manufacture, and commercialize two T-cell engager (TCE) products targeting agreed-upon antigens, based on Amberstone's T-MATE™ technology platform, for all human therapeutic uses. Amberstone, a Delaware-based biotechnology company founded in December 2018 and led by CEO George Wu, focuses on innovative antibody therapies for oncology. Fosun Pharma stated that the collaboration aims to leverage both parties' technical strengths and R&D capabilities to advance new oncology products and enrich its therapeutic pipeline.
Read sourceShanghai Henlius Licenses T-Cell Engager Rights from Amberstone in $236 Million Deal
Shanghai Henlius Biotech, a subsidiary of Fosun Pharma, announced a licensing agreement with Amberstone for the development of two T-cell engager (TCE) products. Under the agreement, Amberstone grants Henlius an exclusive global license to research, develop, manufacture, and commercialize the products using Amberstone's TMATE™ technology platform. Henlius will pay up to $236.16 million in total consideration, including an upfront payment of up to $4 million and up to $232.16 million in research, development, and regulatory milestone payments tied to progress such as preclinical candidate nomination, clinical studies, regulatory approvals, and commercialization.
Read sourceFosun Pharma Subsidiary Signs Exclusive License Deal with Amberstone for T-Cell Engager Products
On September 23, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its subsidiary, Henlius, has entered into a Collaboration and License Agreement with Amberstone. Under the agreement, Henlius obtains an exclusive global license to research, develop, manufacture, and commercialize two T-cell engager (TCE) products targeting specific tumor antigens, using Amberstone's proprietary T-MATE™ technology platform. The T-MATE™ platform is a tumor microenvironment-activated technology designed to enhance the selective targeting of TCE molecules to tumor tissues while reducing effects on normal tissues, potentially addressing the narrow therapeutic window and safety limitations of traditional TCE products in solid tumor treatment. The collaboration focuses on two targets designated by Henlius for oncology applications.
Show 6 older updatesHide older updates
Fosun Pharma unit Henlius gets exclusive license from Amberstone for up to $236 million
On September 23, 2026, Fosun Pharma announced that its controlling subsidiary Shanghai Henlius Biotech has entered into a Collaboration and License Agreement with Amberstone. Under the deal, Henlius receives an exclusive worldwide license for all human uses to research, develop, manufacture, and commercialize two collaboration products targeting a specified target, based on Amberstone's T-MATE™ technology platform. Henlius will pay Amberstone up to $236.16 million in upfront fees, R&D expenses, and development and regulatory milestones, including an upfront payment of up to $4 million and up to $232.16 million in R&D and regulatory milestones tied to PCC, clinical studies, regulatory approvals, and launch progress. Additionally, Henlius may pay up to $652 million in tiered sales milestone payments based on annual net sales of the collaboration products in the licensed territory.
Fosun Pharma unit Henlius gets exclusive license from Amberstone in deal worth up to $236 million
Fosun Pharma announced on September 23 that its subsidiary Henlius has signed a Cooperation and License Agreement with Amberstone. Under the agreement, Henlius receives an exclusive global license for all human uses to research, develop, produce, and commercialize two products based on Amberstone's T-MATE™ technology platform for a specified target. Henlius will pay Amberstone up to $236.16 million in upfront fees, R&D costs, and development and regulatory milestones, including an upfront payment of up to $4 million and combined R&D and milestone payments of up to $232.16 million, contingent on progress in R&D, preclinical candidate selection, clinical studies, regulatory approvals, and market launches. Additionally, Henlius will pay Amberstone up to $652 million in tiered sales-based milestone payments based on annual net sales of the products in the licensed territory.
Read sourceFosun Pharma unit Henlius signs exclusive license deal with Amberstone for TCE products
Shanghai Fosun Pharmaceutical (Fosun Pharma) announced in an evening filing that its controlling subsidiary, Shanghai Henlius Biotech, signed a Cooperation and License Agreement with Amberstone on September 23, 2026. Under the agreement, Amberstone grants Henlius an exclusive global license, covering all human-use fields, to research, develop, manufacture, and commercialize two T-cell engager (TCE) products based on Amberstone's T-MATE technology platform for a specified target. Amberstone, a biotechnology company founded in December 2018 and headquartered in Delaware, USA, focuses on developing innovative antibody therapies for oncology. Its Chairman and CEO is George Wu. Fosun Pharma stated that the collaboration aims to leverage the technical advantages and R&D capabilities of both parties to advance new oncology therapies and enrich the group's product pipeline in this therapeutic area. The report was sourced from Shanghai Securities News via China Securities Network.
Read sourceFosun Pharma Subsidiary Henlius Signs Global License Deal with Amberstone for T-Cell Engager Products
On September 23, 2026, Shanghai Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, has entered into a Collaboration and License Agreement with Amberstone. Under the agreement, Henlius obtains an exclusive global license, for all human uses, to research, develop, manufacture, and commercialize two T-cell engager (TCE) products targeting two undisclosed tumor antigens. The products will be designed using Amberstone's proprietary T-MATE technology platform, a tumor microenvironment-activated platform that modulates TCE molecule activation in the tumor microenvironment versus peripheral tissues. This approach aims to enhance selective targeting of tumor tissues and reduce impact on normal tissues, potentially addressing the narrow therapeutic window and safety limitations of traditional TCE products in solid tumor treatment.
Read sourceHenlius and Amberstone Sign TCE Collaboration and License Agreements
Shanghai Henlius Biotech announced on September 23, 2026, that it has entered into collaboration and license agreements with Amberstone for two T-cell engager (TCE) products based on the T-MATE technology platform. Under the agreements, Amberstone grants Henlius an exclusive sublicensable license for early-stage research and development targeting two specific targets designated by Henlius. The total research and development costs, along with development and regulatory milestone payments, are capped at $232 million. Sales milestone payments could reach up to $652 million, with additional royalty payments at a low single-digit percentage of annual net sales. The partnership covers global research, development, manufacturing, and commercialization of the two TCE products.
Read sourceFosun Pharma unit Henlius signs licensing deal with Amberstone for T-cell engager products
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced on September 23 that its controlling subsidiary, Shanghai Henlius Biotech, has entered into a collaboration and license agreement with Amberstone. The agreement grants Henlius an exclusive, worldwide license for all human therapeutic uses to develop, manufacture, and commercialize two T-cell engager products targeting a designated antigen, based on Amberstone's T-MATE technology platform. Under the terms, Henlius will pay up to $236 million in upfront fees, R&D expenses, and development and regulatory milestone payments, plus up to $652 million in sales milestone payments. The announcement was reported by Jiemian News and carried on East Money's A-share company news feed.
Read source